Benign Prostatic Hyperplasia Bph Treatment Devices Market Report: Market Size & Forecast 2026

BPH is a noncancerous enlargement of the prostate gland that obstructs urine flow, affecting more than half of men by age 60 and up to 90 percent by age 85. Treatment devices span minimally invasive technologies, including laser systems, water vapor therapy, and prostatic urethral lift devices, as well as conventional endoscopic resection tools and catheters used in post-operative care. The global market is valued at approximately $4.8 billion in 2025 and projected to expand at a compound annual growth rate near 7.2 percent through the early 2030s, reflecting sustained clinical demand and device adoption.

• •Prostate enlargement is among the most common urological conditions in aging male populations, generating recurring demand for device-based interventions
• •Device categories include laser systems, ablation instruments, urethral lift implants, catheters, and endoscopic resection equipment
• •Market growth is supported by rising global healthcare expenditure and widening insurance coverage for urological procedures

A key driver is the expanding elderly demographic, as BPH prevalence rises sharply with age and longer life expectancies increase the patient pool. Growing preference for minimally invasive procedures, which reduce hospital stays, blood loss, and recovery time compared to traditional surgery, accelerates adoption of newer device categories. Improved diagnostic capabilities and rising awareness of treatment options, particularly in developing regions, further contribute to market expansion.

• •The global aging trend directly expands the at-risk population, with urological conditions representing a leading cause of hospitalization among older men
• •Technological advances in laser and thermal ablation therapies offer comparable efficacy to open surgery with significantly reduced patient morbidity
• •Expanding insurance reimbursement for minimally invasive urological procedures in North America, Europe, and parts of Asia-Pacific lowers financial barriers to treatment

Product segments typically include laser therapy devices, prostatic urethral lift devices, water vapor thermal therapy systems, endoscopic resection tools, and related urological catheters. North America commands the largest market share, supported by advanced healthcare infrastructure, high procedure volumes, and early adoption of innovative devices. Europe represents a strong secondary market, while the Asia-Pacific region is anticipated to grow at the fastest pace due to improving healthcare access, rising medical tourism, and growing urological care investments.

• •North America leads the global market, followed by Europe; the Asia-Pacific region is the fastest-growing segment driven by rising healthcare spending and medical device penetration
• •Laser-based and minimally invasive thermal ablation systems are capturing an increasing share of total procedure volume
• •Hospitals and ambulatory surgical centers are the dominant end-user channels, with outpatient settings gaining share due to cost efficiencies

What are the recent trends and outlook?

Future growth will be propelled by the continued transition from open surgery to office-based and ambulatory procedures, supported by evolving reimbursement frameworks and patient preference. Innovations in laser wavelength technology, targeted thermal ablation, and next-generation implantable devices are expected to broaden treatment options and improve clinical outcomes. The market is also likely to benefit from growing research into combination therapies and personalized treatment protocols tailored to individual prostate anatomies.

• •Office-based and outpatient procedures are increasingly preferred, driving demand for compact, user-friendly device platforms that can be deployed outside traditional hospital settings
• •Emerging technologies, including advanced laser systems and biodegradable implantable devices, are anticipated to reshape the competitive landscape over the forecast period
• •Data-driven treatment planning and integration with digital surgical navigation tools represent a growing area of investment among leading manufacturers